A rare BTK A428D mutation causes resistance to all BTK-targeted therapies, finds a new study. China is reviewing the first CAR-T therapy for gastric cancer, and research reveals why BET inhibitors fail and targets AML's DNMT3A mutation.
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
The University of Cincinnati Cancer Center’s Blood Cancer Healing Center added research laboratories and the UC Osher Wellness Suite and Learning Kitchen. The expansion joins clinical services launched in July 2024 and adds new research, wellness and community programming space.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
Calidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform at the 2026 AACR Immuno-Oncology conference, demonstrating tumor-localized BiTE expression and IL-15 superagonist delivery. The company plans to submit an IND application for CLD-401 by end of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07763184 |
mNGS for IFD in Patients With Hematological Malignancies |
NOT_YET_RECRUITING | |
| NCT07719946 |
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers |
RECRUITING | PHASE2 |
| NCT07709195 |
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant |
RECRUITING | PHASE2 |
| NCT07636486 |
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07635511 |
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies |
NOT_YET_RECRUITING | PHASE3 |
| NCT07621289 |
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe |
NOT_YET_RECRUITING | |
| NCT07541326 |
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France |
NOT_YET_RECRUITING | NA |
| NCT07539779 |
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07456982 |
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting |
ACTIVE_NOT_RECRUITING | NA |
| NCT07362732 |
Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection |
NOT_YET_RECRUITING | EARLY_PHASE1 |
